aWHO/WPRO Japanese Encephalitis Regional Refernce Laboratory, 187 Osongsaengmyeong2-ro, Chungbuk 363-951, Korea
bDivision of Arboviruses, National Institute of Health, Korea Centers for Disease Control and Prevention, 187 Osongsaengmyeong2-ro, Chungbuk 363-951, Korea
cDepartment of Pediatrics, Inha University Medical School, Incheon, Korea
dDepartment of Biomedical Sciences, Hallym University, Chuncheon, Korea
© 2014 Published by Elsevier B.V. on behalf of Korea Centers for Disease Control and Prevention.
This is an Open Access article distributed under the terms of the CC-BY-NC License (http://creativecommons.org/licenses/by-nc/3.0).
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristics |
Group |
Total | |
---|---|---|---|
Inactivated vaccine | Live vaccine | ||
Number of children | 15 | 14 | 29 |
Number of doses in primary schedule | 3 | 2 | – |
Mean (range) age at time of first dose (mo) | 16.4 (10.4–24.2) | 14.7 (11.9–24.3) | 15.6 (10.4–24.3) |
Mean (range) age at time of last dose (mo) | 31 (19.6–67.7)a | 24.9 (18.4–31.6) | 28 (18.4–67.7) |
Interval between sampling and last dose (mo) | 27.9 (3.2–47.0) | 21.3 (3.0–47.1) | 24.7 (3.0–47.1) |